Anzeige
Mehr »
Login
Dienstag, 18.02.2025 Börsentäglich über 12.000 News von 687 internationalen Medien
1,5 Mio. Unzen indiziert, 5,2 Mio. Unzen geschätzt - und es wächst weiter: Die Goldaktie mit neuem Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMBV | ISIN: DK0061804770 | Ticker-Symbol: LDBA
Tradegate
14.02.25
18:52 Uhr
5,645 Euro
-0,020
-0,35 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
H LUNDBECK A/S B Chart 1 Jahr
5-Tage-Chart
H LUNDBECK A/S B 5-Tage-Chart
RealtimeGeldBriefZeit
5,6305,69007:12
5,6455,68517.02.

Aktuelle News zur H LUNDBECK Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLundbeck gains FDA fast track designation for MSA therapy amlenetug4
MiLundbeck's Potential Treatment for Multiple System Atrophy Granted Fast Track Designation2
MiH. Lundbeck A/S: Lundbeck's potential treatment amlenetug for Multiple System Atrophy receives Fast Track Designation from the FDA109The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA)....
► Artikel lesen
H LUNDBECK Aktie jetzt für 0€ handeln
05.02.H. LUNDBECK A/S: Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties4
05.02.Lundbeck-Aktien fallen nach Umsatzverfehlung im vierten Quartal5
05.02.Lundbeck stock falls after Q4 revenue miss4
05.02.H. Lundbeck A/S: Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)77Key highlights Lundbeck's total revenue grew by +14% CER[1] (+11% DKK) to DKK 22,004 million in 2024, with all regions contributing to growth United States: DKK 11,325 million (+16% CER; +15% DKK) Europe:...
► Artikel lesen
04.02.H. LUNDBECK A/S: Lundbeck announces changes to the Board of Directors1
30.01.H. Lundbeck A/S: Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies95Bexicaserin achieved an overall median seizure reduction of 59.3 percent in countable motor seizures over a 12-month open-label extension (OLE) treatment period....
► Artikel lesen
09.01.H. Lundbeck A/S: Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD146H. Lundbeck A/S (Lundbeck) announces that the U.S. Food and Drug Administration (FDA) plans to host a Psychopharmacologic Drugs Advisory Committee (PDAC) meeting to seek input on issues related to the...
► Artikel lesen
05.12.24H. LUNDBECK A/S: Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations17
03.12.24Lundbeck acquires all outstanding shares of Longboard Pharma3
03.12.24H. LUNDBECK A/S: Efficacy of Vyepti highlighted by new clinical trial results in severe migraine2
02.12.24H. Lundbeck A/S: Lundbeck completes acquisition of Longboard165A significant step forward in Lundbeck's Focused Innovator strategy and advancing the goal of building a robust neuro-rare franchise The lead asset, bexicaserin, holds blockbuster potential and is...
► Artikel lesen
28.11.24H LUNDBECK A/S: Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled7
27.11.24H LUNDBECK A/S: Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy2
13.11.24H. Lundbeck A/S: Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024189Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 Key highlights Lundbeck's total revenue grew by +13% CER[1] (+10% DKK) to DKK 16,463 million...
► Artikel lesen
06.11.24Longboard Pharmaceuticals HSR waiting period expires for Lundbeck deal5
31.10.24H LUNDBECK A/S: Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention4
24.10.24Lundbeck slashes value of $250M Abide buyout after pain setback7
Seite:  Weiter >>
55 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1